Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Mycophenolate Sodium for GvHD Prophylaxis
NCT00856505Phase 2Unknown
- Sponsor
- University Hospital Freiburg
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in graft-versus-host disease (GVHD), sponsored by University Hospital Freiburg. Primary endpoint: Toxicity according to CTCAE v3.0 at 1 year. Status: unknown.
02
Drugs
everolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00856505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856505.